---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-082717"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:31:50.099975+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nkarta appoints Shawn Rose as CMO & Head of R&D; David Shook resigns effective June 6

## Summary
- Shawn Rose, M.D. Ph.D, joins as CMO and Head of R&D starting June 23, 2025, succeeding David Shook.
- Dr. Shook resigned to pursue other oncology opportunities; will consult through July 11.
- Dr. Rose brings experience from Vividion, Magenta, Janssen, and BMS, with work on Sotyktu, Stelara, Tremfya.
- Company reaffirms focus on allogeneic NK cell therapies for autoimmune disease.
- Annual meeting results: all three Class II director nominees elected; Ernst & Young ratified as auditor.

## SEC filing metadata
- accession: 0000950170-25-082717
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/0000950170-25-082717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/nktx-20250603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-082717
- JSON: https://secwatch.observer/filing/0000950170-25-082717.json
- Plain text: https://secwatch.observer/filing/0000950170-25-082717.txt

## Key facts
- Executive change
  David Shook resigned as Chief Medical Officer and Head of Research & Development at Nkarta, Inc..
  - Action: resigned
  - Role: Chief Medical Officer and Head of Research & Development
  source text: David Shook, M.D. notified Nkarta, Inc. (the “Company”) of his decision to resign as Chief Medical Officer and Head of Research & Development of the Company to pursue other opportunities in the oncology space.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/0000950170-25-082717-index.htm
- Executive change
  Shawn Rose was appointed as Chief Medical Officer and Head of Research and Development at Nkarta, Inc..
  - Action: appointed
  - Role: Chief Medical Officer and Head of Research and Development
  source text: Shawn Rose, M.D. Ph.D. has been appointed by the Company to succeed Dr. Shook as Chief Medical Officer and Head of Research and Development starting on June 23, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/0000950170-25-082717-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.